QNCX Stock Overview
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Quince Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.13 |
52 Week High | US$1.93 |
52 Week Low | US$0.84 |
Beta | 1.27 |
1 Month Change | -15.04% |
3 Month Change | 0.89% |
1 Year Change | -25.17% |
3 Year Change | -96.67% |
5 Year Change | n/a |
Change since IPO | -96.56% |
Recent News & Updates
Recent updates
Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation
Nov 21Cortexyme to change name and ticker symbol next month
Jul 27Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
Mar 01Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors
Dec 15We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
Dec 15Cortexyme: A Challenging Path Forward
Nov 17Cortexyme: Positive Lessons To Be Learned From Disappointing Results
Nov 01Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease
Oct 11Cortexyme: Alzheimer's Readout In November A Binary Event
Sep 12We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth
Aug 23Cortexyme EPS beats by $0.02
May 10We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate
May 10Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares
Mar 10Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth
Feb 09Cortexyme: A Fresh Perspective In Alzheimer's
Jan 12Have Insiders Been Buying Cortexyme, Inc. (NASDAQ:CRTX) Shares This Year?
Dec 18Cortexyme weighed down by Citi downgrade
Dec 11Shareholder Returns
QNCX | US Biotechs | US Market | |
---|---|---|---|
7D | -6.6% | -0.5% | 0.6% |
1Y | -25.2% | 9.6% | 29.5% |
Return vs Industry: QNCX underperformed the US Biotechs industry which returned 10.2% over the past year.
Return vs Market: QNCX underperformed the US Market which returned 29.8% over the past year.
Price Volatility
QNCX volatility | |
---|---|
QNCX Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QNCX has not had significant price volatility in the past 3 months.
Volatility Over Time: QNCX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 21 | Dirk Thye | https://www.quincetx.com |
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022.
Quince Therapeutics, Inc. Fundamentals Summary
QNCX fundamental statistics | |
---|---|
Market cap | US$51.44m |
Earnings (TTM) | -US$28.02m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.7x
P/E RatioIs QNCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QNCX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$28.03m |
Earnings | -US$28.02m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.65 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did QNCX perform over the long term?
See historical performance and comparison